pdufa.bio
HomePDUFA Calendar › EXEL

EXEL FDA calendar & decision history

Exelixis · 1 upcoming · 2 past FDA decisions

Upcoming FDA catalysts

EXEL · Dec 3, 2026Zanzalintinib (XL092) + atezolizumab - (STELLAR-303) — 2L metastatic colorectal cancer

FDA decision history (2)

Jul 2, 2025✓ ApprovedFDA decisionMar 26, 2025✓ ApprovedFDA decision
Full PDUFA calendar →All FDA decisions →Phase readouts →
See the full 2026 PDUFA calendar →

This page aggregates EXEL's FDA catalysts from pdufa.bio's own calendar and decision archive. Each item links to its source page. Facts and dates only; verify against primary FDA / SEC / company filings.